Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$668.58 USD

668.58
1,298,850

+5.33 (0.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $667.86 -0.72 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Walgreens (WBA) Expands Medical Care Offerings in California

by Zacks Equity Research

Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.

Sweta Killa headshot

5 Dividend Growth Stocks for Safe Income Amid Volatility

by Sweta Killa

The Kroger (KR), NVIDIA (NVDA), Jones Lang LaSalle (JLL), Paychex (PAYX) and McKesson (MCK) could be compelling picks amid market volatility.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Zacks Equity Research

Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

Zacks Equity Research

Bruker (BRKR) to Support Biopharma Industries With New Buyout

by Zacks Equity Research

Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Zacks Equity Research

Why McKesson (MCK) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.

Zacks Equity Research

Medtronic (MDT) Reports Positive Findings Backing RDN System

by Zacks Equity Research

Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.

Zacks Equity Research

Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays

by Zacks Equity Research

In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.

Zacks Equity Research

Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod

by Zacks Equity Research

Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.

Zacks Equity Research

Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage

by Zacks Equity Research

Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

NextGen (NXGN) Introduces New Integrated Care EHR Solution

by Zacks Equity Research

NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.

Zacks Equity Research

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty

by Zacks Equity Research

Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.

Zacks Equity Research

AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock For Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.

Zacks Equity Research

Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.

Zacks Equity Research

Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Zacks Equity Research

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Zacks Equity Research

Cardinal Health (CAH) to Extend Medical Distribution Presence

by Zacks Equity Research

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Zacks Equity Research

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

by Zacks Equity Research

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) robust international performance and strength in its GYN Surgical business.

Zacks Equity Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.